When: Confirmed close above $28.75 on expanding volume

Then: Trigger re-engagement / add exposure

SELL/trim; reduce exposure to 1.5-2% of book from current level; do not add at $26.79

• Q2 2026 FCF of $0.30B covers only ~12% of $2.45B quarterly dividend—far below the 1.27x TTM coverage that anchors on the strongest quarter
• Q4 2025 impairment of $4.47B and Q2 2026 impairment of $4.33B on the $43B Seagen acquisition signal capital allocation failure, not irrelevant non-cash noise
• $71B in remaining goodwill creates ongoing write-down risk if Seagen integration underperforms
• Albert Bourla's $1M buy represents ~1% of his liquid wealth vs $100M+ net worth—symbolic gesture, not substantive signal; total insider cluster under $5M vs $152B market cap
• Price rejected at $27.20 twice (August 10-11); Bollinger upper band at $27.39; trading at 83% toward resistance—adding into the upper band with tight $25.40 stop is asymmetric downside risk
• 9.25x forward P/E built on estimates assuming $8.8B impairments don't recur and non-COVID portfolio scales—Street estimates historically optimistic for pharma in transition
• 6.42% dividend yield is a yellow flag, not a screaming buy—market is pricing dividend risk, not offering a gift
• $28.75 stop is the invalidation level for the bear thesis, not maximum pain for a long; 2.5 ATR stop ($25.40) is appropriate for high-conviction long, not for adding at resistance
• Conservative sizing at 1.5-2% of book ($1.5-2M on $100M) limits downside in tail events where 0.28 beta provides no protection
• Wait for: (1) pullback to $25.40-$26.00 with RSI above 55, or (2) confirmed close above $27.40 with expanding volume; reassess at Q3 2026 earnings in October

→ vs aggressive: TTM FCF coverage of 1.27x is misleading because it includes the strongest quarter (Q4 2025 at $4.50B); Q2 2026 FCF of $0.30B shows 93% decline and only 12% dividend coverage

→ vs aggressive: Impairments are not irrelevant 'non-cash' noise—they signal $4.47B and $4.33B write-downs on $43B Seagen acquisition in audited financials, evidence of value-destroying M&A with $71B goodwill still at risk

→ vs aggressive: Bourla's $1M buy is ~1% of liquid wealth for a $100M+ net worth CEO, and total insider cluster is under $5M vs $152B market cap—sentiment, not substance

→ vs aggressive: Adding at $26.79 into Bollinger upper band at $27.39 with 83% of the way to resistance is asymmetric downside risk; $25.40 stop gives almost no room for normal volatility

→ vs aggressive: 9.25x forward P/E is built on optimistic Street estimates assuming $8.8B impairments don't recur; 6.42% yield is market pricing dividend risk, not a gift

→ vs aggressive: Position sizing at 3-4% of book creates materially worse downside if wrong; 0.28 beta provides no protection in tail events; circular reasoning to use yield to justify concentration risk

→ vs aggressive: 2027 rate thesis is speculation; positioning for a 2027 macro call today ignores near-term FCF deterioration, technical resistance, and Q3 2026 earnings risk

TRIM (25-33%) into upper-band resistance ($27.20-$27.39), HOLD core position at 2.0-2.5% of book, WAIT for Q3 earnings catalyst in October before any sizing increases; use $25.40 as invalidation level (breakout zone) for the long thesis.

• Q2 FCF of $0.30B against $2.45B dividend obligation is a yellow flag regardless of seasonality, with coverage ratio of ~12%
• Seagen impairment pattern ($4.47B in Q4 2025 + $4.33B in Q2 2026 on $43B acquisition) signals capital allocation problems, not just housekeeping
• $71B in goodwill remains on balance sheet with potential for more write-downs if Seagen integration disappoints
• Insider buying cluster (Albert Bourla + 3 insiders within days of difficult quarter) is meaningful signal given CEO's informational advantage
• Valuation attractive at 9.25x forward earnings with 6.42% yield and beta of 0.28 on absolute basis
• Aggressive analyst's $25.40 stop is at breakout zone—buying at 83% of upper Bollinger with tight 5% stop is worst risk/reward setup
• Conservative analyst's FCF trajectory argument is the strongest underappreciated risk in the setup
• Binary catalyst window (Q3 earnings October) justifies current 1.5-2.0% sizing discipline regardless of conviction level
• Technical setup is constructive with all moving averages rising, MACD above zero, and confirmed breakout from multi-month base
• The existing plan already rejects pure SELL conviction by citing yield and valuation as 'floor against outright Sell conviction'

→ vs aggressive: The $25.40 stop is at the breakout zone, which is exactly where price would naturally retest after any pullback from resistance—setting up to get stopped out at the worst possible moment

→ vs conservative: The 'yield is a yellow flag' framing is overly negative when the same yield combined with insider conviction and stabilizing business is exactly what defensive investors want

→ vs conservative: The $28.75 stop makes sense for someone who has already sold and wants re-entry, but for current holders the relevant question is where the long thesis breaks ($25.40), not where underweight thesis is invalidated ($28.75)